Discovery of N-benzyl-2-[(4S)-4-(1H-indol-3-ylmethyl)-5-oxo-1-phenyl-4,5-dihydro-6H-[1,2,4]triazolo[4,3-a][1,5]benzodiazepin-6-yl]-N-isopropylacetamide, an orally active, gut-selective CCK1 receptor agonist for the potential treatment of obesity (Q45579688)
Jump to navigation
Jump to search
scientific article published on 28 September 2010
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Discovery of N-benzyl-2-[(4S)-4-(1H-indol-3-ylmethyl)-5-oxo-1-phenyl-4,5-dihydro-6H-[1,2,4]triazolo[4,3-a][1,5]benzodiazepin-6-yl]-N-isopropylacetamide, an orally active, gut-selective CCK1 receptor agonist for the potential treatment of obesity |
scientific article published on 28 September 2010 |
Statements
1 reference
Discovery of N-benzyl-2-[(4S)-4-(1H-indol-3-ylmethyl)-5-oxo-1-phenyl-4,5-dihydro-6H-[1,2,4]triazolo[4,3-a][1,5]benzodiazepin-6-yl]-N-isopropylacetamide, an orally active, gut-selective CCK1 receptor agonist for the potential treatment of obesity (English)
1 reference
Richard L Elliott
1 reference
Kimberly O Cameron
1 reference
Janice E Chin
1 reference
Jeremy A Bartlett
1 reference
Elena E Beretta
1 reference
Yue Chen
1 reference
Paul Da Silva Jardine
1 reference
Jeffrey S Dubins
1 reference
Melissa L Gillaspy
1 reference
Diane M Hargrove
1 reference
Amit S Kalgutkar
1 reference
Janet A LaFlamme
1 reference
Mary E Lame
1 reference
Kelly A Martin
1 reference
Tristan S Maurer
1 reference
Nancy A Nardone
1 reference
Robert M Oliver
1 reference
Dexue Sun
1 reference
Andrew G Swick
1 reference
Catherine E Trebino
1 reference
Yingxin Zhang
1 reference
28 September 2010
1 reference
1 reference
Identifiers
1 reference